GSK 692342

Drug Profile

GSK 692342

Alternative Names: 692342; GSK M72; GSK-692342; M72/AS01E; Mtb72F/AS02A

Latest Information Update: 02 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 21 Jul 2015 Phase-II development is ongoing in Belgium, Gambia, India, Philippines, Switzerland and South Africa
  • 01 Jun 2015 GlaxoSmithKline completes a phase-II trial in Tuberculosis in India (NCT01262976)
  • 31 Aug 2014 Aeras & GlaxoSmithKline initiate enrolment in a sub-study in Healthy volunteers in South Africa (NCT02097095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top